Clinical outcomes of standard triple therapy plus probiotics or concomitant therapy for Helicobacter pylori infection

Jae Hyun Jung, In Kuk Cho, Chang Hee Lee, Gwan Gyu Song, Ji Hyun Lim

    Research output: Contribution to journalArticlepeer-review

    16 Citations (Scopus)

    Abstract

    Background/Aims: The efficacy of standard triple therapy (STT) in treating Helicobacter pylori infection has decreased. Many investigators have attempted to increase the eradication rate. We investigated the outcomes of concomitant therapy (CT) and STT combined with probiotics (STP) as a first-line treatment for H. pylori infection. Methods: We reviewed the medical records of 361 patients who received either STP (n=286) or CT (n=75). The STP group received STT combined with a probiotic preparation for 1 week. The CT group received STT and metronidazole for 1 week. Results: The intention-to-treat and per-protocol eradication rates were 83.6% (95% confidence interval [CI], 79.0 to 87.7) and 87.1% (95% CI, 81.2 to 89.7) in the STP group and 86.7% (95% CI, 78.7 to 93.3) and 91.4% (95% CI, 83.6 to 97.1) in the CT group (p=0.512 and p=0.324), respectively. The frequency of adverse effects was higher in the CT group (28.2%) than in the STP group (12.8%) (p=0.002). Conclusions: STP and CT are encouragingly efficacious as first-line treatments for H. pylori infection. Therefore, adding probiotics to STT may be a feasible option to avoid side effects. (Gut Liver 2018;12:165-172).

    Original languageEnglish
    Pages (from-to)165-172
    Number of pages8
    JournalGut and liver
    Volume12
    Issue number2
    DOIs
    Publication statusPublished - 2018 Mar

    Bibliographical note

    Publisher Copyright:
    © This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License

    Keywords

    • Helicobacter pylori
    • Metronidazole
    • Probiotics

    ASJC Scopus subject areas

    • Hepatology
    • Gastroenterology

    Fingerprint

    Dive into the research topics of 'Clinical outcomes of standard triple therapy plus probiotics or concomitant therapy for Helicobacter pylori infection'. Together they form a unique fingerprint.

    Cite this